BRENTWOOD, Tenn. / Sep 30, 2024 / Business Wire / Ardent Health (NYSE: ARDT) has been added as a member of the broad-market Russell 3000® Index and Russell 2000®, effective Monday, September 23, 2024, as part of the quarterly U.S. Russell Index Initial Public Offering (IPO) update.
“We are pleased to join the Russell 3000® Index and look forward to building awareness around the Ardent growth story while increasing our exposure to new investor audiences,” said Ardent President and Chief Executive Officer Marty Bonick. “Ardent Health’s inclusion is an important milestone and underscores our strategic focus on delivering sustainable growth and value as we build a consumer-focused ecosystem of care in the communities we serve.”
Membership in the U.S. all-cap Russell 3000® Index, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell’s U.S. indexes. Russell indexes are part of FTSE Russell, a leading global index provider.
For more information on the Russell 2000® and 3000® Indexes and the Russell indexes quarterly updates for IPOs, go to https://www.lseg.com/en/ftse-russell/russell-reconstitution/ipo-additions.
About Ardent Health
Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and more than 200 sites of care with over 1,700 affiliated providers across six states. For more information, please visit www.ardenthealth.com.
Last Trade: | US$16.27 |
Daily Volume: | 562,645 |
November 06, 2024 August 14, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB